Literature DB >> 2783885

Involvement of both Tac and non-Tac interleukin 2-binding peptides in the interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes.

M Yagita1, K Itoh, M Tsudo, L B Schaub, C D Platsoucas, C M Balch, E A Grimm.   

Abstract

Interleukin 2 (IL-2) receptor expression was examined on recombinant IL-2 (rIL-2)-propagated tumor-infiltrating lymphocytes (TIL) from eight metastatic melanoma and three sarcoma samples. All 11 TIL expanded with similar growth rates. rIL-2 propagated TIL from five of eight metastatic melanoma specimens contained no Tac antigen-positive lymphocytes as determined by immunofluorescence and flow cytometry performed multiple times during the 4 to 8 week culture period. However, "Tac-negative" TIL did express the non-Tac IL-2-binding peptide, p70-75 as determined by [125I]IL-2 cross-linking and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. IL-2-binding assays revealed that these "Tac-negative" TIL expressed only an intermediate affinity IL-2 receptor. In contrast, TIL from the other three of eight melanoma and all three sarcoma contained one-third Tac-positive cells as assessed by flow cytometry analysis, and expressed surface non-Tac (p70-75) and Tac (p55) peptides by [125I]IL-2 cross-linking. These "Tac-positive" TIL displayed both the high and intermediate affinity IL-2 receptors. However, rIL-2-dependent growth of both "Tac-negative" and "Tac-positive" TIL was significantly inhibited by anti-Tac mAb, suggesting a transient Tac expression on the "Tac-negative" TIL. Additionally, due to the limits of our methodology, we cannot rule out the possibility of a constitutive expression of a low level of Tac, with an indicible expression of higher levels. Addition of culture supernatants from phytohemagglutinin- and phorbol myristate acetate-stimulated peripheral blood mononuclear cells to the "Tac-negative" TIL-induced detectable Tac expression within 48 h. These results indicate that both non-Tac and Tac IL-2 receptors play important roles during IL-2-dependent proliferation of TIL.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783885

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

2.  Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.

Authors:  E A Grimm; J M Bruner; J Carinhas; J A Köppen; W G Loudon; L Owen-Schaub; P A Steck; R P Moser
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Lymphokine production by human melanoma tumor-infiltrating lymphocytes.

Authors:  M A Salmeron; T Morita; H Seki; C D Platsoucas; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

5.  Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.

Authors:  P F Mansfield; M G Rosenblum; J L Murray; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; A Milani; E Pirone; D Nitti; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

7.  Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; C Enthammer; M Cassatella; D Nitti; M Lise; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

8.  Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and tumor-infiltrating lymphocytes activated by PSK.

Authors:  Y Kariya; N Okamoto; T Fujimoto; N Inoue; T Kihara; K Sugie; M Yagita; H Kanzaki; T Mori; A Uchida
Journal:  Jpn J Cancer Res       Date:  1991-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.